Anti-Inflammatory Treatment With Colchicine in Acute Myocardial Infarction A Pilot Study

作者：Deftereos Spyridon; Giannopoulos Georgios^*; Angelidis Christos; Alexopoulos Nikolaos; Filippatos Gerasimos; Papoutsidakis Nikolaos; Sianos George; Goudevenos John; Alexopoulos Dimitrios; Pyrgakis Vlasios; Cleman Michael W; Manolis Antonis S; Tousoulis Dimitrios; Lekakis John

来源：Circulation, 2015, 132(15): 1395-1403.

DOI：10.1161/CIRCULATIONAHA.115.017611

• area under curve
• creatine kinase, MB form
• gadolinium
• magnetic resonance imaging
• neutrophil
• troponin T

Background-Inflammatory processes have been identified as key mediators of the deleterious effects of ischemia/reperfusion in ST-segment-elevation myocardial infarction. Colchicine is a substance with potent anti-inflammatory properties, suitable for safe use in patients with cardiovascular disease. The purpose of this study was to test the hypothesis that a short course of colchicine treatment could lead to reduced infarct size.
Methods and Results-Patients presenting with ST-segment-elevation myocardial infarction 12 hours from pain onset (treated with primary percutaneous coronary intervention) were randomly assigned to colchicine or placebo for 5 days. The primary outcome parameter was the area under the curve of creatine kinase-myocardial brain fraction concentration. A subset of patients underwent cardiac MRI with late gadolinium enhancement 6 to 9 days after the index ST-segment-elevation myocardial infarction. One hundred fifty-one patients were included (60 in the MRI substudy). The area under the creatine kinase-myocardial brain fraction curve was 3144 (interquartile range [IQR], 1754-6940) ng.h(-1.)mL(-1) in the colchicine group in comparison with 6184 (IQR, 4456-6980) ng.h(-1.)mL(-1) in controls (P<0.001). Indexed MRI-late gadolinium enhancement-defined infarct size was 18.3 (IQR, 7.6-29.9) mL/1.73 m(2) in the colchicine group versus 23.2 (18.5-33.4) mL/1.73 m(2) in controls (P=0.019). The relative infarct size (as a proportion to left ventricular myocardial volume) was 13.0 (IQR, 8.0-25.3) % and 19.8 (IQR, 13.7-29.8) %, respectively (P=0.034).
Conclusions-These results suggest a potential benefit of colchicine in ST-segment-elevation myocardial infarction, but further clinical trials are necessary to draw secure conclusions, especially considering the fact that the present study was not powered to assess clinical end points.

• 出版日期2015-10-13